Clinical trials: Astrocytoma, Grade IV
Astrocytoma, Glioblastoma
Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor
Glioblastomas, the most frequent malignant brain tumor in adults, are widespread in the brain, despite their discrete appearance on computed tomography (CT) or magnetic resonance imaging (MRI).
- Conditions
- Astrocytoma, Glioblastoma, Glioma
- Trial name
- NCT00001148
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Glioblastoma Multiforme
Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme
In this study patients will be treated with 6 weeks of radiation therapy plus temozolomide chemotherapy according to the standard of care.
- Trial name
- NCT02177578
- Testing
- Temozolomide, Subventricular Zone radiation, Neural Progenitor Cell Sparing radiation
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Initial Radiological Diagnosis Eligible for Tumor Resection, Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type)
Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.
Glioblastoma (GBM) is an aggressive cancer with a progression-free survival (PFS) of 7 months and an overall survival (OS) of 15 months. Many therapeutic approaches have failed to improve the prognosis of patients to date.
- Conditions
- Initial Radiological Diagnosis Eligible for Tumor Resection, Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type), Eligible for the Standard of Care Including Concurrent Temoradiation and Adjuvant Temozolomide
- Trial name
- SonoFIRST (NCT04614493)
- Testing
- SonoCloud-9 (SC9) device, Temozolomide according Stupp protocol
- Where
- 7 sites in Belgium, France and 1 more
- Volunteers
- 66 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Glioblastoma Multiforme
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
This is a Phase 1/2 study of selinexor in combination with standard of care (SoC) therapy for newly diagnosed glioblastoma (nGBM) or recurrent glioblastoma (rGBM).
- Trial name
- NCT04421378
- Testing
- Selinexor, Temozolomide (TMZ), Lomustine (CCNU)
- Where
- 18 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- Karyopharm Therapeutics Inc
Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4
Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene
Cilengitide 2000 mg flat i.v. twice weekly is administered over a period of 18 months without interruption. Starting one week after the initiation of Cilengitide, RTX (60 Gy, 2 Gy per fraction) with concurrent daily temozolomide…
- Trial name
- ExCentric (NCT01124240)
- Testing
- Cilengitide
- Where
- Australia
- Volunteers
- 48 people
- Sponsor
- Northern Sydney and Central Coast Area Health Service
Newly Diagnosed and Recurrent Glioblastoma
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
This study will investigate different doses of [177Lu]Lu-NeoB in combination with RT and TMZ in participants with newly diagnosed glioblastoma, with methylated or unmethylated promoter, to assess the safety and efficacy of…
- Trial name
- NCT05739942
- Testing
- [177Lu]Lu-NeoB, [68Ga]Ga-NeoB, Temozolomide
- Where
- 16 sites in United States, France and 4 more
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Glioma
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
To determine the efficacy of Pulse Reduced Dose Rate (PRDR) radiation when given in 27 fraction over 5.5 weeks with concurrent bevacizumab followed by adjuvant bevacizumab until time of progression in patients with recurrent high…
- Trial name
- NCT01743950
- Testing
- Bevacizumab, PRDR
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Wisconsin, Madison
Brain Tumor, Glioma, Malignant
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Pear Bio has developed a 3D microtumor assay and computer vision pipeline through which the response of an individual patient's tumor to different anti-cancer regimens can be tested simultaneously ex vivo.
- Conditions
- Brain Tumor, Glioma, Malignant, Ependymoma, Oligodendroglioma
- Trial name
- PEAR-GLIO (NCT06038760)
- Testing
- Resection
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Ourotech, Inc.
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
3T MRI Biomarkers of Glioma Treatment Response
This pilot clinical trial studies advanced magnetic resonance imaging (MRI) techniques in measuring treatment response in patients with high-grade glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma
- Trial name
- NCT01996527
- Testing
- 3-Tesla magnetic resonance imaging, CEST-MRI, DW-MRI
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Glioblastoma
Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma
Despite advances in neurosurgery , radiotherapy and chemotherapy, the median survival in GBM patients is only 15 months from diagnosis.
- Trial name
- GLIOBLASTOMES (NCT03687099)
- Testing
- no intervention
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Glioblastoma, Astrocytoma, Grade IV
A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM
The purpose of the Cerebral EDV study is to determine the safety and tolerability of EGFR(V)-EDV-Dox in order to establish the best dose level to be used in future studies.
- Trial name
- CerebralEDV (NCT02766699)
- Testing
- EGFR(V)-EDV-Dox
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Engeneic Pty Limited
Glioblastoma
89Zr-RO5323441 PET Imaging in Glioblastoma
The research the investigators propose is a molecular imaging study of RO5323441, an antibody against placental growth factor (PlGF) in patients with recurrent GBM treated with bevacizumab, a drug against vascular endothelial…
- Trial name
- NCT01622764
- Testing
- Molecular imaging with 89Zr-RO5323441
- Where
- Netherlands
- Sponsor
- University Medical Center Groningen
Recurrent Glioblastoma, Glioblastoma Multiforme
Sonodynamic Therapy in Patients With Recurrent GBM
Patients diagnosed with glioblastoma (GBM) are faced with limited treatment options. This pilot study will evaluate the safety and feasibility of combining an investigational drug called 5-ALA with neuronavigation-guided…
- Conditions
- Recurrent Glioblastoma, Glioblastoma Multiforme, GBM
- Trial name
- GBM 001 (NCT06039709)
- Testing
- 5-ALA and Low-Intensity Focused Ultrasound (SDT)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Shayan Moosa, MD
Glioblastoma Multiforme
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following…
- Trial name
- NCT02047214
- Testing
- TPI 287, Bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cortice Biosciences, Inc.
Glioblastoma
A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma
Angiopoietin-2 (Ang-2) is a protein in the body which destabilizes blood vessels and is important in stimulating tumor blood vessels.
- Trial name
- NCT01225510
- Testing
- PF-04856884
- Sponsor
- Pfizer
Glioblastoma, Glioblastoma Multiforme
The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients
This phase I trial investigates the efficacy and safety of brain-targeting epidermal growth factor receptor chimeric antigen receptor immune cells (EGFRvIII-CAR T cells) in treating patients with leptomeningeal disease from…
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant
- Trial name
- CARTREMENDOUS (NCT05063682)
- Testing
- EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes
- Where
- 3 sites in Finland, India
- Volunteers
- 10 people
- Sponsor
- Chembrain LTD
Solid Tumor, Glioblastoma Multiforme
A Trial of Ipatasertib in Combination With Atezolizumab
This is a single centre, proof-of-concept phase I trial of atezolizumab in combination with ipatasertib. There are two parts to this study, the dose escalation phase (Part A) and the dose expansion phase (Part B).
- Conditions
- Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic
- Trial name
- IceCAP (NCT03673787)
- Testing
- ipatasertib, Atezolizumab
- Where
- United Kingdom
- Volunteers
- 87 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Gliosarcoma, Glioblastoma
Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas
Primary Objective: To determine maximum tolerated dose \& dose limiting toxicity of vandetanib when combined with standard dosing of etoposide among patients with recurrent malignant glioma who are on \& not on enzyme-inducing…
- Trial name
- NCT00613223
- Testing
- Vandetanib and Etoposide
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Annick Desjardins
Recurrent Glioblastoma Multiforme
A Prospective, Open-label, Single-arm Clinical Study
the study is a prospective, single-arm, open-label trial, designed to explore the efficacy and safety of Tumor-Treating Fields (TTFields) combined with second-line chemotherapy treatment in recurrent glioblastoma multiforme (GBM)…
- Trial name
- NCT04689087
- Testing
- TTFields
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Recurrent Glioblastoma (WHO-Grade IV Glioma)
Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
Phase II clinical trial on the combination of avelumab and axitinib for the treatment of patients with recurrent glioblastoma (histologically confirmed WHO grade IV glioma), at documented recurrence/progression following prior…
- Trial name
- GliAvAx (NCT03291314)
- Testing
- Axitinib, Avelumab
- Where
- Belgium
- Volunteers
- 52 people
- Sponsor
- Universitair Ziekenhuis Brussel